Who
Barry J. Simon
Director
Company insider
Files Form 4 as: President and COO, ImmunityBio; Director, Viracta Therapeutics; Director, Cue Biopharma.
In numbers
- Trades disclosed
- 103
- Buys
- 0
- Sells
- 27
- Bought
- $0
- Sold
- $21.9M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 27 Jul 2015
- Last trade
- 5 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 6 Oct 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $269K25,000 at $10.75 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $197K25,000 at $7.88 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $197K25,000 at $7.88 | filing |
| 4 Jun 2026filed 5 Jun 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $165K23,033 at $7.18 | filing |
| 4 Jun 2026filed 5 Jun 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $165K23,033 at $7.18 | filing |
| 24 Feb 2026filed 26 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $901K75,000 at $12.01 | filing |
| 24 Feb 2026filed 26 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $901K75,000 at $12.01 | filing |
| 23 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $1.7M165,000 at $10.25 | filing |
| 23 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $1.7M165,000 at $10.25 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —15,243 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $52K6,026 at $8.70 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —15,243 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —15,243 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —15,243 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $52K6,026 at $8.70 | filing |
| 20 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $93K10,000 at $9.25 | filing |
| 20 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $93K10,000 at $9.25 | filing |
| 20 Jan 2026filed 21 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $503K76,967 at $6.54 | filing |
| 20 Jan 2026filed 21 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $591K75,000 at $7.88 | filing |
| 20 Jan 2026filed 21 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $503K76,967 at $6.54 | filing |
News
ImmunityBio (NASDAQ:IBRX) Director Cheryl Cohen Sells 81,056 Shares of StockIBRX · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Barry J. Simon; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.